More than $5.5 million of CIHR funding awarded to NMD4C members to strengthen neuromuscular research capacity in Canada
Congratulations to the recipients of the Fall 2022 CIHR funded project grant competition! Seven projects were awarded (>5.5M) to NMD4C members to advance neuromuscular research in Canada: Drs. Rashmi Kothary and Cynthia Gagnon (steering committee members); Dr. Bernard Brais (investigator); Drs. Elise Duchesne (2 projects funded) and Gerald Pfeffer (working group members); and Drs. Yan Burelle, Nicolas Dumont (2 projects funded), Penney Gilbert, Luc Hébert, Mireille Khacho, Keir Menzies, Louise Moyle, and Toshifumi Yokota (members). Of note, 6/7 of the funded projects were awarded to early-career researchers (Drs. Nicolas Dumont, Elise Duchesne, Mireille Khacho, and Louise Moyle). Further information on the funding recipients can be found below.
Project Title: Extra-neuronal contribution to spinal muscular atrophy disease pathogenesis ($818,550).
Principal Investigator: Dr. Rashmi Kothary; Ottawa Hospital Research Institute
Project Title: Regulation of satellite stem cell fate by LINC complex proteins ($1,071,000).
Principal Investigator: Dr. Penney Gilbert; University of Toronto
Co-Investigators: Drs. Louise Moyle and Aaron Wheeler
Project Title: Therapeutic potential of bioactive lipids as anti-fibrotic therapy for muscle regeneration and dystrophies ($757,350).
Principal Investigator: Dr. Nicolas Dumont; Centre hospitalier universitaire Sainte-Justine (Montréal, Québec)
Project Title: Targeting defective cells to restore myogenesis and muscle function in myotonic dystrophy type 1 ($761,175).
Principal Investigators: Drs. Nicolas Dumont and Elise Duchesne; Centre hospitalier universitaire Sainte-Justine (Montréal, Québec)
Project Title: IMPACT, a supervised rehabilitation program for spastic ataxias: A rater-blinded, randomized controlled trial ($638,776).
Principal Investigators: Drs. Elise Duchesne, Mylene Aubertin, Bernard Brais, and Cynthia Gagnon; Université du Québec à Chicoutimi
Co-Investigators: Drs. Rubens da Silva, Raquel Fonseca, Luc Hébert, Gerald Pfeffer
Project Title: Mitochondrial Quality Control in Muscle Stem Cells: A Determinant of Cell Fate Decision and Tissue Repair Capacity ($692,325).
Principal Investigator: Dr. Yan Burelle; University of Ottawa
Co-Investigators: Drs. Mireille Khacho, Keir Menzies
Project Title: Neutrophil Responses in Doxorubicin-Induced Myopathy ($879,750).
Principal Investigator: Javier Clemente-Casares; University of Alberta
Co-Investigators: Gavin Oudit, Toshifumi Yokota
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.